semaglutide

Semaglutide primary acylation intermediate and Semaglutide dipeptide are Semaglutide N-2 main chain intermediate and N-2 fragment. The primary acylation intermediate was acylated with Semaglutide dipeptide to obtain Semaglutide secondary acylation intermediate and further hydrolyzed to obtain Semaglutide crude product. Acylation, hydrolysis tank, high pressure chromatography system, drying equipment are required. Product Name: Semaglutide primary acylation intermediate (N-2)

Semaglutide Main Chain P29 (N-3) - 1169630-82-3 Semaglutide main chain P29 and Semaglutide side chain (tetrapeptide) are key intermediates in the synthesis of Semaglutide API. The Semaglutide main chain P29 undergoes acylation with the Semaglutide side chain to form the primary acylation intermediate, which is further processed to obtain the final active pharmaceutical ingredient. These high-purity intermediates are specifically designed for pharmaceutical enterprises with

Semaglutide 99% (Sterile) Injection Grade (910463-68-2) Semaglutide (CAS 910463-68-2) is an anti-diabetic medication used for the treatment of type 2 diabetes and chronic weight management. Semaglutide (Sterile) 99% is specifically prepared for the formulation of Semaglutide injection. This product achieves a purity level of 99.0% with an assay range of 95%~105% and peptide content of Semaglutide between 76%~100%. Product Specifications Product Name: Semaglutide primary

Semaglutide secondary acylation intermediate is N-1 intermediate of Semaglutide. The protection group of this prodcut was deprotected to obtain Semaglutide crude product, which was purified by chromatography and freeze dried to obtain API. Secondary acylation intermediate is suitable for the enterprises that have the production capacity and want to own the API approval. Product Name: Semaglutide Secondary Acylation Intermediate (N-1) Assay: 50% End Use: Semaglutide Molecular

Semaglutide 98% (Oral Grade) (910463-68-2) Semaglutide (CAS 910463-68-2) is an anti-diabetic medication used for the treatment of type 2 diabetes and chronic weight management. Semaglutide for oral grade 98% is specifically formulated for markets requiring high standards in oral dosage forms with strict control of raw material impurities. This product maintains a purity level of 98% while meeting the same acceptance criteria as Semaglutide injectable grade 99%. Product

Semaglutide 96% (Oral Grade) (910463-68-2) Semaglutide (CAS 910463-68-2) is an anti-diabetic medication used for the treatment of type 2 diabetes and chronic weight management. Semaglutide Oral Grade 96% is specifically formulated for price-sensitive markets where the tabbing process does not introduce new impurities. This product maintains a purity level of 96% with an assay range of 90% to 100%. Product Specifications Product Name Semaglutide 96% (Oral Grade) CAS Number

Semaglutide Crude Product (N-0.5) (910463-68-2) Semaglutide (CAS 910463-68-2) is an anti-diabetic medication used for the treatment of type 2 diabetes and chronic weight management. This semaglutide crude product is specifically prepared for pharmaceutical enterprises with production capacity seeking API approval. The active pharmaceutical ingredient (API) can be obtained through purification processes including chromatography and freeze drying. This product maintains a

AEEA-AEEA-OH (Semaglutide Tetrapeptide - Side Chain Intermediate) Code: AEEA-AEEA-OH | CAS No.: 1143516-05-5 This compound serves as a key intermediate for the synthesis of the side chain of Semaglutide, a pharmaceutical peptide. Product Specifications Product Name AEEA-AEEA-OH (Semaglutide Tetrapeptide - Side Chain Intermediate) Code AEEA-AEEA-OH CAS No. 1143516-05-5 Assay 98% End Use Semaglutide Molecular Formula C12 H24 N2 O7 Molecular Weight 308.33 Shelf Life 2 Years

Boc-L-His(Boc)-Aib-OH (N-2 Fragment Intermediate) Product Code: 2765344-17-8 This Semaglutide primary acylation intermediate and Semaglutide dipeptide serve as crucial N-2 main chain intermediate and N-2 fragment components in Semaglutide synthesis. The primary acylation intermediate undergoes acylation with Semaglutide dipeptide to produce the Semaglutide secondary acylation intermediate, which is subsequently hydrolyzed to yield the Semaglutide crude product. Required